Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNYNF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for SANOFI ORD (SNYNF) provides access to Sanofi’s disclosures as a foreign private issuer under the Securities Exchange Act of 1934. Sanofi files annual reports on Form 20-F and current reports on Form 6-K pursuant to Rule 13a-16 or 15d-16, furnishing information that it makes public in its home market or through stock exchanges.
Sanofi’s Form 6-K filings incorporate press releases as exhibits, which describe regulatory and clinical events across several therapeutic areas. For example, exhibits reference Tzield as a disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes approved in China, and Dupixent, developed with Regeneron, which advanced in the European Union with a positive CHMP opinion for chronic spontaneous urticaria.
Other filings highlight an update on U.S. regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis, fast track designation in the United States for SAR402663 in neovascular age-related macular degeneration, and positive phase 2a results for brivekimig in hidradenitis suppurativa. These documents show how Sanofi reports on regulatory designations, approvals, and clinical trial outcomes to U.S. investors.
On this page, users can review Sanofi’s Forms 6-K and related exhibits as they appear in the EDGAR system. AI-powered summaries can help explain the focus of each filing, highlight the therapies and indications mentioned, and clarify the significance of regulatory terms such as fast track designation or positive CHMP opinion, making the content more accessible to readers who are not specialists in regulatory language.
Sanofi reported three corporate press developments in September 2025 affecting its late-stage pipeline. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes, marking a regulatory milestone for that indication in China. On September 11, 2025, Sanofi announced that SAR402663 received fast track designation in the U.S. for neovascular age-related macular degeneration, which can accelerate development and review. On September 17, 2025, Sanofi reported positive phase 2a results for brivekimig in hidradenitis suppurativa. The report is signed by Alexandra Roger, Head of Legal Corporate & Finance.
FAQ
What is the current stock price of Sanofi FR (SNYNF)?
